Black Diamond Therapeutics

BDTX

Market cap $180M

Overview Fund Activity

3.16 USD

-0.01

0.32%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

3.21

+0.05

1.58%

1 day

-0.32%

5 days

-2.77%

1 month

14.91%

3 months

36.21%

6 months

84.8%

Year to date

47.66%

1 year

-34.58%

5 years

-89.91%

10 years

-92%

About: Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Employees: 54

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

578% more call options, than puts

Call options by funds: $61K | Put options by funds: $9K

59% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 17

44% more capital invested

Capital invested by funds: $66.3M [Q1] → $95.8M (+$29.5M) [Q2]

33% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 27

11% more funds holding

Funds holding: 84 [Q1] → 93 (+9) [Q2]

4.01% less ownership

Funds ownership: 71.92% [Q1] → 67.91% (-4.01%) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8

153% upside

Avg. target

$9.67

206% upside

High target

$11

248% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Guggenheim Brad Canino	$8	Buy Initiated	4 Sep 2025
HC Wainwright & Co. Robert Burns	$10	Buy Maintained	11 Aug 2025
Raymond James Sean McCutcheon	$11	Outperform Reinstated	1 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about BDTX published over the past 30 days

Zacks Investment Research

Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?

Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.

Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?

Zacks Investment Research

BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?

Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.

BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?

Zacks Investment Research

Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?

Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.

Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?

Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash

Black Diamond Therapeutics' Silvertinib (BDTX-1535) targets non-classical EGFR mutations in NSCLC, addressing an unmet need left by current standard Osimertinib. Preliminary Phase 2 results for Silvertinib are promising, with full enrollment completed and further data expected in Q4 2025. Early data of Silvertinib in the first line setting will be a major catalyst.

Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash

Zacks Investment Research

Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why

Black Diamond (BDTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why

Zacks Investment Research

Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?

Here is how Black Diamond (BDTX) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?

The Motley Fool

Black Diamond (BDTX) Q2 Loss Narrows 47%

Black Diamond (BDTX) Q2 Loss Narrows 47%

Black Diamond (BDTX) Q2 Loss Narrows 47%

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside

Black Diamond Therapeutics's novel EGFR inhibitor shows promise in addressing resistance mutations in NSCLC and glioblastoma, with key phase 2 data expected in Q4 2025. The Servier licensing deal strengthens BDTX's cash position, providing runway into late 2027 and reducing near-term financial risk. Despite a challenging competitive landscape, the Company's targeted approach and early efficacy signals create potential for significant upside if data are positive.

Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D.

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

See News Rankings

Charts implemented using Lightweight Charts™